Behold the Body. Electron microgram of a Biondi body shows a dense core surrounded by filaments that bind gold-labeled secondary antibody to TMEM239 (black dots). [Courtesy of Ghetti et al., 2024.] ...
Mivelsiran docks APP products in early AD. Phase 2 trial asks: Can it treat CAA? LX1001 gene therapy boosts CSF ApoE2, stabilizes AD biomarkers. Intranasal insulin quells systemic inflammation. These ...
Alzheimer’s disease is a long, slow neurodegenerative calamity, and scientists are still hunting for blood biomarkers that reflect all its specific stages. At the Clinical Trials on Alzheimer’s ...
Yes, blood tests for Alzheimer’s disease are ready for prime time. So pronounced Suzanne Schindler, Washington University, St. Louis, in a keynote presentation at CTAD 2024 last month in Madrid. In ...
Rosa-Grilo incorporated Wave-CAIPI into the diagnostic scanning protocol used at UCL’s memory clinic. It comprises four sequences: T1-weighted 3D, T2-weighted 2D, T2-weighted 3D, and 3D FLAIR imaging.
Despite higher rates of clinically diagnosed dementia among people from non-white racial and ethnic groups, historically they have been underrepresented in AD clinical trials. Efforts are underway to ...
Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...
MD - University of North Carolina MBA - Kenan-Flagler Business School @ UNC MS Neuroscience - Tulane University Radiology Residency - Weill Cornell Fellowship Neuroradiology - Massachusetts General ...
It doesn’t replace radiologists or the clinical read, but it augments them,” he told Alzforum before its FDA approval. He would like to see it widely adopted. Other Alzheimer’s clinicians contacted by ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback